Literature DB >> 19621012

Cardiovascular risk factors in patients with chronic kidney disease.

Sarina van der Zee1, Usman Baber, Sammy Elmariah, Jonathan Winston, Valentin Fuster.   

Abstract

Patients with chronic kidney disease have a higher burden of cardiovascular disease, which increases in a dose-dependent fashion with worsening kidney function. Traditional cardiovascular risk factors, including advanced age, diabetes mellitus, hypertension and dyslipidemia, have an important role in the progression of cardiovascular disease in patients who have a reduced glomerular filtration rate, especially in those with mild-to-moderate kidney disease. In patients with severe kidney disease, nontraditional or 'novel' risk factors, including inflammation, oxidative stress, vascular calcification, a prothrombotic milieu, and anemia, seem to confer additional risk. In this Review, we highlight factors that increase cardiovascular risk in patients with a reduced estimated glomerular filtration rate. In addition, we discuss therapeutic strategies for reducing cardiovascular risk in patients with kidney disease, whose unique atherosclerotic phenotype might require an approach that differs from traditional models developed in populations with normal kidney function. Therapeutic paradigms for patients with chronic kidney disease and cardiovascular risk factors must be evaluated in randomized trials, from which such patients have often been excluded.

Entities:  

Mesh:

Year:  2009        PMID: 19621012     DOI: 10.1038/nrcardio.2009.121

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  93 in total

1.  Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.

Authors:  F Zannad; M Kessler; P Lehert; J P Grünfeld; C Thuilliez; A Leizorovicz; P Lechat
Journal:  Kidney Int       Date:  2006-07-19       Impact factor: 10.612

2.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

6.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

7.  Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort.

Authors:  U Baber; J A de Lemos; A Khera; D K McGuire; T Omland; R D Toto; S S Hedayati
Journal:  Kidney Int       Date:  2007-12-12       Impact factor: 10.612

8.  Cardiovascular disease and subsequent kidney disease.

Authors:  Essam F Elsayed; Hocine Tighiouart; John Griffith; Tobias Kurth; Andrew S Levey; Deeb Salem; Mark J Sarnak; Daniel E Weiner
Journal:  Arch Intern Med       Date:  2007-06-11

9.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.

Authors:  Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

10.  Blood pressure and mortality risk on peritoneal dialysis.

Authors:  Udaya P Udayaraj; Retha Steenkamp; Fergus J Caskey; Chris Rogers; Dorothea Nitsch; David Ansell; Charles R V Tomson
Journal:  Am J Kidney Dis       Date:  2008-11-22       Impact factor: 8.860

View more
  24 in total

1.  Association between age-related decline of kidney function and plasma malondialdehyde.

Authors:  Guolin Li; Yaqin Chen; Hui Hu; Li Liu; Xiaofei Hu; Jun Wang; Wang Shi; Dazhong Yin
Journal:  Rejuvenation Res       Date:  2012-04-24       Impact factor: 4.663

2.  Osteoblast-like differentiation of cultured human coronary artery smooth muscle cells by bone morphogenetic protein endothelial cell precursor-derived regulator (BMPER).

Authors:  Seimi Satomi-Kobayashi; Mitsuo Kinugasa; Reiko Kobayashi; Kinta Hatakeyama; Yusuke Kurogane; Tatsuro Ishida; Noriaki Emoto; Yujiro Asada; Yoshimi Takai; Ken-ichi Hirata; Yoshiyuki Rikitake
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

Review 3.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

4.  The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients.

Authors:  Erhan Tatar; Meltem Sezis Demirci; Fatih Kircelli; Ozkan Gungor; Mustafa Yaprak; Gulay Asci; Ali Basci; Mehmet Ozkahya; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2011-07-22       Impact factor: 2.370

Review 5.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

6.  Salusin-β Promotes Vascular Calcification via Nicotinamide Adenine Dinucleotide Phosphate/Reactive Oxygen Species-Mediated Klotho Downregulation.

Authors:  Haijian Sun; Feng Zhang; Yu Xu; Shuo Sun; Huiping Wang; Qiong Du; Chenxin Gu; Stephen M Black; Ying Han; Haiyang Tang
Journal:  Antioxid Redox Signal       Date:  2019-12-20       Impact factor: 8.401

Review 7.  Management of cardiovascular disease in patients with kidney disease.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-02-19       Impact factor: 32.419

8.  A novel clinical prediction rule for 30-day mortality following balloon aortic valuloplasty: the CRRAC the AV score.

Authors:  Sammy Elmariah; Steven A Lubitz; Amil M Shah; Marc A Miller; Dheeraj Kaplish; Sharad Kothari; Pedro R Moreno; Annapoorna S Kini; Samin K Sharma
Journal:  Catheter Cardiovasc Interv       Date:  2011-03-16       Impact factor: 2.692

9.  Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes.

Authors:  Raija Lithovius; Iiro Toppila; Valma Harjutsalo; Carol Forsblom; Per-Henrik Groop; Ville-Petteri Mäkinen
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

10.  Assessment of vascular function in patients with chronic kidney disease.

Authors:  Kristen L Jablonski; Emily Decker; Loni Perrenoud; Jessica Kendrick; Michel Chonchol; Douglas R Seals; Diana Jalal
Journal:  J Vis Exp       Date:  2014-06-16       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.